|
| Before propensity score matching | After propensity score matching |
Patients without prior OAC | Patients with prior OAC | value | Patients without prior OAC | Patients with prior OAC | value |
N = 7023 | N = 675 | N = 638 | N = 638 |
|
Demographic |
Male sex, n (%) | 4097 (58.3) | 403 (59.7) | 0.491 | 386 (60.5) | 372 (58.3) | 0.425 |
Age (years), median (IQR) | 63 (50–75) | 80 (72–86) | <0.001 | 80 (72–86) | 80 (72–86) | 1.000 |
Race (non-Caucasian), n (%) | 1603 (22.8) | 59 (8.7) | <0.001 | 49 (7.7) | 59 (9.2) | 0.315 |
Body mass index (kg/m2), median (IQR) | 27.1 (24.2–30.7) | 27.7 (25.0–31.2) | 0.011 | 26.9 (24.5–30.5) | 26.7 (25.0–31.3) | 0.168 |
Baseline comorbidities, n (%) |
Hypertension | 3176 (45.2) | 542 (80.3) | <0.001 | 433 (68.0) | 516 (80.9) | 0.053 |
Diabetes mellitus | 1257 (17.9) | 198 (29.3) | <0.001 | 168 (27.0) | 190 (30.3) | 0.198 |
Heart failure | 128 (1.8) | 46 (6.8) | <0.001 | 35 (5.5) | 39 (6.1) | 0.632 |
Stroke/TIA | 439 (6.3) | 131 (19.4) | <0.001 | 92 (14.4) | 122 (19.1) | 0.437 |
Chronic kidney disease | 369 (5.3) | 115 (17.0) | <0.001 | 69 (11.0) | 109 (17.0) | 0.487 |
Vascular disease | 543 (7.7) | 102 (15.1) | <0.001 | 93 (14.6) | 88 (13.8) | 0.688 |
Hypercholesterolemia | 2096 (29.8) | 344 (51.0) | <0.001 | 288 (45.1) | 326 (51.1) | 0.085 |
Current smoking habit | 407 (5.8) | 35 (5.2) | 0.243 | 21 (3.3) | 31 (4.9) | 0.071 |
COPD/SAHS | 419 (6.0) | 104 (15.4) | <0.001 | 81 (12.7) | 84 (13.2) | 0.802 |
History of malignant disease | 822 (11.7) | 139 (20.6) | <0.001 | 129 (20.2) | 129 (20.2) | 1.000 |
Liver disease | 238 (3.4) | 33 (4.9) | 0.001 | 30 (4.7) | 31 (4.9) | 0.795 |
Dysthyroidism | 334 (4.8) | 40 (5.9) | 0.177 | 37 (5.8) | 40 (6.3) | 0.724 |
Any dependency level | 819 (11.7) | 210 (31.1) | <0.001 | 177 (28.2) | 194 (30.6) | 0.365 |
Concomitant treatment at admission, n (%) |
Beta-blockers | 865 (12.3) | 328 (48.6) | <0.001 | 132 (20.7) | 311 (48.7) | <0.001 |
ACEi/ARBs | 2320 (33.0) | 369 (54.7) | <0.001 | 311 (48.7) | 350 (54.9) | 0.086 |
Antiplatelet therapy | 1229 (17.5) | 74 (11.0) | <0.001 | 199 (31.2) | 72 (11.3) | <0.001 |
Laboratory parameters at admission |
Creatinine (mg/dL), median (IQR) | 0.90 (0.72–1.17) | 1.19 (0.90–1.64) | <0.001 | 0.98 (0.78–1.42) | 1.20 (0.88–1.66) | <0.001 |
Hemoglobin (g/dL), median (IQR) | 14.0 (12.0–15.0) | 13.0 (11.0–14.0) | <0.001 | 13.0 (12.0–15.0) | 13.0 (11.0–14.0) | <0.001 |
Platelet count (×109/L), median (IQR) | 203.0 (155.0–265.8) | 179.0 (136.0–240.0) | <0.001 | 195.0 (145.0–260.8) | 181.0 (138.0–241.0) | 0.019 |
Elevated D-dimer, n (%) | 3921 (55.8) | 358 (53.0) | 0.036 | 425 (66.6) | 342 (53.6) | <0.001 |
Elevated procalcitonin, n (%) | 1048 (14.9) | 126 (18.7) | 0.001 | 103 (16.1) | 123 (19.3) | 0.299 |
Elevated C-reactive protein, n (%) | 5841 (83.2) | 608 (90.1) | <0.001 | 566 (88.7) | 576 (90.3) | 0.657 |
Elevated troponins, n (%) | 527 (7.5) | 107 (15.9) | <0.001 | 54 (8.5) | 100 (15.7) | <0.001 |
Elevated transaminases, n (%) | 2598 (37.0) | 220 (32.6) | 0.009 | 216 (33.9) | 210 (32.9) | 0.023 |
Elevated ferritin, n (%) | 2306 (32.8) | 207 (30.7) | 0.424 | 198 (31.0) | 198 (31.0) | 1.000 |
Elevated lactate dehydrogenase, n (%) | 4414 (62.9) | 464 (68.7) | 0.005 | 427 (66.9) | 440 (69.0) | 0.466 |
|